This new approval expands Ozempic’s use, adding to its previous indications for improving glycemic control in Type 2 diabetes and reducing major cardiovascular events in people with heart disease, according to a Jan. 28 news release from Novo Nordisk.
The basis of the approval was due to a phase 3 trial that demonstrated the drug significantly reduced the risk of kidney disease progression and cardiovascular death by 24%, compared to a placebo, over three years.
Ozempic was first approved by the FDA in 2017 for blood sugar control in Type 2 diabetes. It received a cardiovascular indication in 2020 and is now the most broadly indicated GLP-1 receptor agonist for managing diabetes, kidney disease and heart risk.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
